


# Elbasvir-Grazoprevir in HCV GT 1,4, or 6 in PWID on Opiate Agonist Therapy C-EDGE CO-STAR

# Elbasvir-Grazoprevir in HCV GT 1, 4, or 6 in PWID on Opiate Agonist Therapy

## C-EDGE CO-STAR: Study Features

- **Design:** Randomized, phase 3, placebo-controlled, double-blind, multi-site trial using a fixed-dose combination of elbasvir-grazoprevir in treatment-naïve chronic HCV genotype 1, 4, or 6 in persons who inject drugs who are receiving opiate agonist therapy
- **Entry Criteria**
  - Chronic HCV Genotype 1, 4, or 6
  - No prior treatment
  - 18 years or older
  - Opiate Agonist Therapy for  $\geq 3$  months and kept  $\geq 80\%$  of appointments
  - HCV RNA  $\geq 10,000$  IU/mL
  - Cirrhosis allowed with goal 20% of subjects with cirrhosis
  - HIV infection allowed
- **Primary End-Point:** SVR12

# Elbasvir-Grazoprevir in HCV GT 1, 4, or 6 in PWID on Opiate Agonist Therapy C-EDGE CO-STAR: Study Features




## Drug Dosing

Grazoprevir-elbasvir (100/50 mg): fixed dose combination; one pill once daily


# Elbasvir-Grazoprevir in HCV GT 1, 4, or 6 in PWID on Opiate Agonist Therapy C-EDGE CO-STAR: Results in Immediate-Treatment Group

C-EDGE CO-STAR: SVR12 Results (Assumes Reinfections are Failures)



# Elbasvir-Grazoprevir in HCV GT 1, 4, or 6 in PWID on Opiate Agonist Therapy C-EDGE CO-STAR: Results in Immediate-Treatment Group

C-EDGE CO-STAR: SVR12 Results (Assumes Reinfections are Responses)



# Elbasvir-Grazoprevir in HCV GT 1, 4, or 6 in PWID on Opiate Agonist Therapy

## C-EDGE CO-STAR: Results in Deferred-Treatment Group

C-EDGE CO-STAR: SVR12 Results (Assumes Reinfections are Failures)

